Psoriatic arthritis imaging: a review of scoring methods.
about
Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds EnSpondylitic psoriatic arthritis presenting as acute urinary retentionValue of entheseal ultrasonography and serum cartilage oligomeric matrix protein in the preclinical diagnosis of psoriatic arthritis.Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled perioPsoriatic arthritis therapy: NSAIDs and traditional DMARDs.Psoriatic arthritis assessment tools in clinical trials.Psoriatic arthritis and imaging.Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people.Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).Imaging in psoriatic arthritis.Recent advances in imaging in psoriatic arthritis.Orthopaedic interventions in patients with psoriatic arthritis: a descriptive report from the SPAR cohort.Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.Striking difference of periarticular bone density change in early psoriatic arthritis and rheumatoid arthritis following anti-rheumatic treatment as measured by digital X-ray radiogrammetry.Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial.Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study.Radiographic development during three decades in a patient with psoriatic arthritis mutilans.Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
P2860
Q26862017-373C0285-AA34-4793-9454-B6D99E632931Q33628708-A90852E8-14AA-496D-9A35-726AB4F9A426Q34340028-01F13E97-9D11-4FD3-9B4B-501D998FA851Q34538249-4800B1C4-8B04-452A-A5C3-691BB34C1DC1Q35579450-4659577D-09FC-4A9D-9C60-628C2727775EQ35579462-7067809C-89E9-4C91-86B8-134D958584BDQ36040064-94648BF3-FEBC-422A-AFFC-B4EC6311207CQ36182389-7ADB684E-84C0-46FA-8C35-7F5E58A66748Q37172521-2FB867EF-B041-490E-ABEE-300CAFBC36A5Q37267600-39377BCE-4493-4AB6-A1A4-69817CAA16CCQ37465379-50BC9EFB-9C57-4370-A768-E20F62524902Q37465550-882CD43D-DB03-4F5E-A619-166B464FC4F4Q37980390-22CB638A-00F8-46BC-99CD-2F611707BEB6Q38032570-88ED943D-305E-4449-8B1D-1827A130D033Q39367830-E576A550-DE42-44DA-A2BF-DE1F3A64200EQ40095048-C36148CD-EB40-4FB0-9A0B-93B77A49E484Q40350800-85D4DF25-C813-4E5E-B4E7-70317B0959AEQ40740817-FEBFD181-6A4A-499B-A4D7-02F6ADE04843Q41449533-4993DD1C-0237-4A5B-9D45-0C402F8E94C1Q41454181-94CFE6BD-30A2-4398-9768-72B70F0AF34AQ41478116-1E42D452-3610-47D5-BB1C-D9B4778FAC05Q42007138-50F41C88-7A10-4C0B-8521-BCA9E05141E6Q46585904-F9CAEEB5-D18E-47F5-A38F-21F78F30FC4DQ47148249-87D87D7E-3B0E-487D-884C-58AFF438D561Q51738114-C9A3057A-3781-46E2-BA63-A181A605E01BQ57169747-87C0BC55-122F-4846-8C65-3B90579D7779
P2860
Psoriatic arthritis imaging: a review of scoring methods.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Psoriatic arthritis imaging: a review of scoring methods.
@ast
Psoriatic arthritis imaging: a review of scoring methods.
@en
type
label
Psoriatic arthritis imaging: a review of scoring methods.
@ast
Psoriatic arthritis imaging: a review of scoring methods.
@en
prefLabel
Psoriatic arthritis imaging: a review of scoring methods.
@ast
Psoriatic arthritis imaging: a review of scoring methods.
@en
P2093
P2860
P356
P1476
Psoriatic arthritis imaging: a review of scoring methods.
@en
P2093
Wassenberg S
van der Heijde D
P2860
P304
P356
10.1136/ARD.2004.030809
P407
P478
64 Suppl 2
P577
2005-03-01T00:00:00Z